NO20002413D0 - Antistoffer mot Moraxella proteiner og anvendelse derav, samt sett for pÕvisning av antigen og farmasøytisk preparat som inneholder antistoffer - Google Patents

Antistoffer mot Moraxella proteiner og anvendelse derav, samt sett for pÕvisning av antigen og farmasøytisk preparat som inneholder antistoffer

Info

Publication number
NO20002413D0
NO20002413D0 NO20002413A NO20002413A NO20002413D0 NO 20002413 D0 NO20002413 D0 NO 20002413D0 NO 20002413 A NO20002413 A NO 20002413A NO 20002413 A NO20002413 A NO 20002413A NO 20002413 D0 NO20002413 D0 NO 20002413D0
Authority
NO
Norway
Prior art keywords
proteins
antibodies
well
omps
antigen
Prior art date
Application number
NO20002413A
Other languages
English (en)
Other versions
NO20002413L (no
Inventor
Eric J Hansen
Merja Helminen
Isobel Maciver
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of NO20002413L publication Critical patent/NO20002413L/no
Publication of NO20002413D0 publication Critical patent/NO20002413D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20002413A 1991-08-15 2000-05-09 Antistoffer mot Moraxella proteiner og anvendelse derav, samt sett for pÕvisning av antigen og farmasøytisk preparat som inneholder antistoffer NO20002413D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/745,591 US5552146A (en) 1991-08-15 1991-08-15 Methods and compositions relating to useful antigens of Moraxella catarrhalis
PCT/US1992/006869 WO1993003761A1 (en) 1991-08-15 1992-08-14 METHODS AND COMPOSITIONS RELATING TO USEFUL ANTIGENS OF $i(MORAXELLA CATARRHALIS)

Publications (2)

Publication Number Publication Date
NO20002413L NO20002413L (no) 2000-05-09
NO20002413D0 true NO20002413D0 (no) 2000-05-09

Family

ID=24997358

Family Applications (2)

Application Number Title Priority Date Filing Date
NO940502A NO308413B1 (no) 1991-08-15 1994-02-14 Antigen blanding, DNA-segment som koder for et antigen, rekombinant vektor og vertscelle som innbefatter DNA-segmentet samt anvendelser av et antigen
NO20002413A NO20002413D0 (no) 1991-08-15 2000-05-09 Antistoffer mot Moraxella proteiner og anvendelse derav, samt sett for pÕvisning av antigen og farmasøytisk preparat som inneholder antistoffer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO940502A NO308413B1 (no) 1991-08-15 1994-02-14 Antigen blanding, DNA-segment som koder for et antigen, rekombinant vektor og vertscelle som innbefatter DNA-segmentet samt anvendelser av et antigen

Country Status (14)

Country Link
US (3) US5552146A (no)
EP (1) EP0612250B1 (no)
JP (1) JP3499868B2 (no)
KR (1) KR100271888B1 (no)
AT (1) ATE140627T1 (no)
AU (1) AU666329B2 (no)
CA (1) CA2115565C (no)
DE (1) DE69212495T2 (no)
DK (1) DK0612250T3 (no)
ES (1) ES2092696T3 (no)
FI (1) FI106844B (no)
GR (1) GR3021423T3 (no)
NO (2) NO308413B1 (no)
WO (1) WO1993003761A1 (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693654B1 (fr) * 1992-07-20 1994-08-26 Oreal Médicament, notamment immunomodulateur, contenant des enveloppes ou fractions d'enveloppes de bactéries filamenteuses non photosynthétiques et non fructifiantes, et sa préparation.
DK0624376T3 (da) * 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
US5712118A (en) * 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5607846A (en) * 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6121427A (en) * 1994-10-24 2000-09-19 Connaught Laboratories Limited Major outer membrane protein CD of branhamella
US6335018B1 (en) 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6290970B1 (en) * 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
KR100500000B1 (ko) * 1996-05-03 2005-12-12 안텍스 바이오로직스 인코퍼레이션 모락셀라카타르할리스외측막단백질-16폴리펩티드,이의유전자서열및이의용도
US6004562A (en) * 1996-08-16 1999-12-21 The Research Foundation Of The State University Of New York Outer membrane protein B1 of Moraxella catarrhalis
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
EP0948625B1 (en) 1996-12-20 2011-01-26 The Board Of Regents, The University Of Texas System Uspa1 and uspa2 antigens of moraxella catarrhalis
GB9810084D0 (en) 1998-05-11 1998-07-08 Cortecs Uk Ltd Proteins
US6627728B1 (en) 1998-05-12 2003-09-30 Smithkline Beecham Biologicals S.A. Compounds from moraxella catarrhalis
GB9810285D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9812440D0 (en) * 1998-06-09 1998-08-05 Smithkline Beecham Biolog Novel compounds
WO2000056360A2 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccine against antigens from bacteriae
GB9914945D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
GB9921691D0 (en) 1999-09-14 1999-11-17 Smithkline Beecham Sa Novel compounds
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP1961427A3 (en) 2002-08-02 2009-11-04 GlaxoSmithKline Biologicals S.A. Neisserial vaccine compositions comprising a combination of antigens
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP3020411A1 (en) 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccine
EA015561B1 (ru) 2006-01-17 2011-08-30 Арне Форсгрен НОВЫЙ ПОВЕРХНОСТНЫЙ БЕЛОК HAEMOPHILUS INFLUENZAE (БЕЛОК E; pE)
WO2009000825A2 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
AU2009262893B2 (en) 2008-05-30 2015-05-21 The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CN102869378A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
BR112019025193A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
EP3980044A1 (en) 2019-06-05 2022-04-13 GlaxoSmithKline Biologicals SA Saponin purification
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030556A (en) * 1989-03-30 1991-07-09 Danielle Beaulieu Species-specific DNNA probe for the detection of Branhamella catarrhalis

Also Published As

Publication number Publication date
FI940681A0 (fi) 1994-02-14
FI940681A (fi) 1994-04-07
NO20002413L (no) 2000-05-09
US5759813A (en) 1998-06-02
AU2487892A (en) 1993-03-16
NO940502L (no) 1994-03-28
NO940502D0 (no) 1994-02-14
DE69212495D1 (de) 1996-08-29
FI106844B (fi) 2001-04-30
ES2092696T3 (es) 1996-12-01
US5599693A (en) 1997-02-04
US5552146A (en) 1996-09-03
ATE140627T1 (de) 1996-08-15
CA2115565A1 (en) 1993-03-04
GR3021423T3 (en) 1997-01-31
WO1993003761A1 (en) 1993-03-04
AU666329B2 (en) 1996-02-08
EP0612250A1 (en) 1994-08-31
CA2115565C (en) 2007-08-07
JPH07501210A (ja) 1995-02-09
KR100271888B1 (ko) 2000-11-15
EP0612250B1 (en) 1996-07-24
DK0612250T3 (da) 1996-11-25
JP3499868B2 (ja) 2004-02-23
DE69212495T2 (de) 1997-03-06
NO308413B1 (no) 2000-09-11

Similar Documents

Publication Publication Date Title
NO20002413L (no) Antistoffer mot Moraxella proteiner og anvendelse derav, samt sett for pÕvisning av antigen og farmasøytisk preparat som inneholder antistoffer
Alderete et al. Identification and properties of Trichomonas vaginalis proteins involved in cytadherence
DE69635783D1 (de) Antigen omp26 aus haemophilus influenzae
AU585512B2 (en) Antigenic proteins and vaccines containing them and protective antibodies directed to them for prevention of coccidiosis caused by eimeria tenella and eimeria necatrix
ATE183241T1 (de) Impstoff gegen streptococcus suis-infektion
FI924457A (fi) Kompositioner och behandlingsfoerfarande foer lunginflammation i djur
NO954318L (no) Immunogent preparat av OspC-antigenvaksiner for forhindring og behandling av Lymesykdom, samt rekombinante fremgangsmåter for fremstilling av slike antigener
ATA171686A (de) Verfahren zur herstellung von gegen pseudomonas aeruginosa infektionen wirksamen praeparationen
AU3379693A (en) Vaccines and diagnostic assays for haemophilus influenzae
ATE111606T1 (de) Ein gattungsspezifisches listeria-antigen, identifiziert durch monoklonale antikörper.
HUP0102235A1 (hu) Moraxella catarrhalis BASBO27-fehérjék és -gének, továbbá antigének, ellenanyagok és alkalmazások
ATE103817T1 (de) Gegen pseudomonas aeruginosa-infektionen wirksame praeparationen sowie immunglobulin-g-haeltige, gegen bakterium pseudomonas aeruginosa wirksame praeparationen.
Ha Use of Monoclonal Antibodies against Infectious Agent
WO1996034884A3 (en) Synthetic peptides of m. gallisepticum, antibodies thereto, their preparation and use
Kothari et al. Immunoscreening of a S. aureus gene bank with sera from endocarditis patients to isolate clones encoding antigens.
TH3933EX (th) วัคซีนที่มีขอบเขตของการออกฤทธิ์กว้างที่ใช้ต่อต้านโรคโกโนเรีย
SE9202318L (sv) Nya peptider, diagnostiska antigen, användning därav, vacciner och medikamenter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application